Does glycemic control reverse dispersion of ventricular repolarization in type 2 diabetes?

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Miki, Takayuki ^a   Tobisawa, Toshiyuki ^a   Sato, Tatsuya ^a   Tanno, Masaya ^a   Yano, Toshiyuki ^a   Akasaka, Hiroshi ^a   Kuno, Atsushi ^a   Ogasawara, Makoto ^a   Murase, Hiromichi ^a   Saitoh, Shigeyuki ^b   Miura, Tetsuji ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

Glycemic control; QT dispersion; Type 2 diabetes; Ventricular repolarization

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; AUTONOMIC NEUROPATHY; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; EXERCISE ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART MUSCLE ISCHEMIA; HEART REPOLARIZATION; HUMAN; LONGITUDINAL STUDY; MALE; NEUROGENIC BLADDER; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; QRS COMPLEX; QT DISPERSION; QT INTERVAL; RETROSPECTIVE STUDY; RR INTERVAL; SYSTOLIC BLOOD PRESSURE; T WAVE; T WAVE AMPLITUDE; TRIACYLGLYCEROL BLOOD LEVEL; VENTRICULAR REPOLARIZATION; AGED; BLOOD; ELECTROCARDIOGRAPHY; GLYCEMIC INDEX; HEART VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; GLYCEMIC INDEX; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VENTRICULAR DYSFUNCTION;

EID: 84908661802     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-014-0125-8     Document Type: Article

References (45)

1. IDF Diabetes Atlas 2013, International Diabetes Federation, Brussels, Belgium.
2. Preis SR, Hwang SJ, Coady S, Pencina MJ, D'Agostino RB, Savage PJ, Levy D, Fox CS. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735. 10.1161/CIRCULATIONAHA.108.829176, 19307472.
3. Miki T, Yuda S, Kouzu H, Miura T. Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 2013, 18:149-166. 10.1007/s10741-012-9313-3, 22453289.
4. Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW. Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care 2012, 35:2564-2569. 10.2337/dc12-0118, 22875229.
5. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. 10.1016/S0140-6736(98)07019-6.
6. The ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 Diabetes. N Engl J Med 2008,358:2560-2572. 10.1056/NEJMoa0802987.
7. The Action to Control Cardiovascular Risk in Diabetes Study Group: Effects of intensive glucose lowering in type 2 Diabetes. N Engl J Med 2008,358:2545-2559. 10.1056/NEJMoa0802743.
8. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139. 10.1056/NEJMoa0808431, 19092145.
9. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013, 369:1317-1326. 10.1056/NEJMoa1307684, 23992601.
10. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013, 369:1327-1335. 10.1056/NEJMoa1305889, 23992602.
11. Schwartz PJ, Wolf S. QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 1978, 57:1074-1077. 10.1161/01.CIR.57.6.1074, 639227.
12. Zhang Y, Post WS, Blasco-Colmenares E, Dalal D, Tomaselli GF, Guallar E. Electrocardiographic QT interval and mortality: a meta-analysis. Epidemiology 2011, 22:660-670. 10.1097/EDE.0b013e318225768b, 21709561.
13. Montanez A, Ruskin JN, Hebert PR, Lamas GA, Hennekens CH. Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Arch Intern Med 2004, 164:943-948. 10.1001/archinte.164.9.943, 15136301.
14. Okin PM, Devereux RB, Lee ET, Galloway JM, Howard BV. Electrocardiographic repolarization complexity and abnormality predict all-cause and cardiovascular mortality in diabetes: the strong heart study. Diabetes 2004, 53:434-440. 10.2337/diabetes.53.2.434, 14747295.
15. Cox AJ, Azeem A, Yeboah J, Soliman EZ, Aggarwal SR, Bertoni AG, Carr JJ, Freedman BI, Herrington DM, Bowden DW. Heart rate-corrected QT interval is an independent predictor of all-cause and cardiovascular mortality in individuals with type 2 diabetes: the diabetes heart study. Diabetes Care 2014, 37:1454-1461. 10.2337/dc13-1257, 24574343.
16. Cardoso CR, Salles GF, Deccache W. Prognostic value of QT interval parameters in type 2 diabetes mellitus: results of a long-term follow-up prospective study. J Diabetes Complications 2003, 17:169-178. 10.1016/S1056-8727(02)00206-4, 12810239.
17. Giunti S, Gruden G, Fornengo P, Barutta F, Amione C, Ghezzo G, Cavallo-Perin P, Bruno G. Increased QT interval dispersion predicts 15-year cardiovascular mortality in type 2 diabetic subjects: the population-based Casale Monferrato Study. Diabetes Care 2012, 35:581-583. 10.2337/dc11-1397, 22301117.
18. Castro Hevia J, Antzelevitch C, Tornés Bárzaga F, Dorantes Sánchez M, Dorticós Balea F, Zayas Molina R, Quiñones Pérez MA, Fayad Rodríguez Y. Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol 2006, 47:1828-1834. 10.1016/j.jacc.2005.12.049, 16682308.
19. Barbhaiya C, Po JR, Hanon S, Schweitzer P. Tpeak-Tend and Tpeak-Tend/QT ratio as markers of ventricular arrhythmia risk in cardiac resynchronization therapy patients. Pacing Clin Electrophysiol 2013, 36:103-108. 10.1111/pace.12031, 23106253.
20. Smetana P, Schmidt A, Zabel M, Hnatkova K, Franz M, Huber K, Malik M. Assessment of repolarization heterogeneity for prediction of mortality in cardiovascular disease: peak to the end of the T wave interval and nondipolar repolarization components. J Electrocardiol 2011, 44:301-308. 10.1016/j.jelectrocard.2011.03.004, 21511064.
21. Panikkath R, Reinier K, Uy-Evanado A, Teodorescu C, Hattenhauer J, Mariani R, Gunson K, Jui J, Chugh SS. Prolonged Tpeak-to-tend interval on the resting ECG is associated with increased risk of sudden cardiac death. Circ Arrhythm Electrophysiol 2011, 4:441-447. 10.1161/CIRCEP.110.960658, 21593198.
22. Mitsumata K, Saitoh S, Ohnishi H, Akasaka H, Miura T. Effects of parental hypertension on longitudinal trends in blood pressure and plasma metabolic profile: mixed-effects model analysis. Hypertension 2012, 60:1124-1130. 10.1161/HYPERTENSIONAHA.112.201129, 23006727.
23. Consensus statement: Report and recommendations of the San Antonio conference on diabetic neuropathy. American Diabetes Association American Academy of Neurology. Diabetes Care 1988, 11:592-597.
24. Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003, 111:351-357. 10.1055/s-2003-42726, 14520602.
25. Rautaharju PM, Zhang ZM. Linearly scaled, rate-invariant normal limits for QT interval: eight decades of incorrect application of power functions. J Cardiovasc Electrophysiol 2002, 13:1211-1218. 10.1046/j.1540-8167.2002.01211.x, 12521335.
26. Rautaharju PM, Surawicz B, Gettes LS, Bailey JJ, Childers R, Deal BJ, Gorgels A, Hancock EW, Josephson M, Kligfield P, Kors JA, Macfarlane P, Mason JW, Mirvis DM, Okin P, Pahlm O, van Herpen G, Wagner GS, Wellens H. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009, 53:982-991. 10.1016/j.jacc.2008.12.014, 19281931.
27. Festa A, D'Agostino R, Rautaharju P, Mykkänen L, Haffner SM. Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol 2000, 86:1117-1122. 10.1016/S0002-9149(00)01170-X, 11074210.
28. Tekin A, Tekin G, Sezgin AT, Müderrisoğlu H. Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. Pharmacol Res 2008, 57:393-397. 10.1016/j.phrs.2008.04.001, 18487058.
29. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest 2004, 27:175-181. 10.1007/BF03346265, 15129815.
30. Psallas M, Tentolouris N, Papadogiannis D, Doulgerakis D, Kokkinos A, Cokkinos DV, Katsilambros N. QT dispersion: comparison between participants with Type 1 and 2 diabetes and association with microalbuminuria in diabetes. J Diabetes Complications 2006, 20:88-97. 10.1016/j.jdiacomp.2005.05.012, 16504837.
31. Giunti S, Bruno G, Lillaz E, Gruden G, Lolli V, Chaturvedi N, Fuller JH, Veglio M, Cavallo-Perin P. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 2007, 30:2057-2063. 10.2337/dc07-0063, 17485572.
32. Suys B, Heuten S, De Wolf D, Verherstraeten M, de Beeck LO, Matthys D, Vrints C, Rooman R. Glycemia and corrected QT interval prolongation in young type 1 diabetic patients: what is the relation?. Diabetes Care 2006, 29:427-429. 10.2337/diacare.29.02.06.dc05-1450, 16443902.
33. Najeed SA, Khan IA, Molnar J, Somberg JC. Differential effect of glyburide (glibenclamide) and metformin on QT dispersion: a potential adenosine triphosphate sensitive K + channel effect. Am J Cardiol 2002, 90:1103-1106. 10.1016/S0002-9149(02)02776-5, 12423711.
34. Bloomfield DM, Krishna R, Hreniuk D, Hickey L, Ghosh K, Bergman AJ, Miller J, Gutierrez MJ, Stoltz R, Gottesdiener KM, Herman GA, Wagner JA. A thorough QTc study to assess the effect of sitagliptin, a DPP4 inhibitor, on ventricular repolarization in healthy subjects. J Clin Pharmacol 2009, 49:937-946. 10.1177/0091270009337511, 19602719.
35. Ring A, Brand T, Macha S, Breithaupt-Groegler K, Simons G, Walter B, Woerle HJ, Broedl UC. The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study. Cardiovasc Diabetol 2013, 12:70. 10.1186/1475-2840-12-70, 23617452.
36. Geisen K, Végh A, Krause E, Papp JG. Cardiovascular effects of conventional sulfonylureas and glimepiride. Horm Metab Res 1996, 28:496-507. 10.1055/s-2007-979841, 8911987.
37. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589. 10.1056/NEJMoa0806470, 18784090.
38. Karpanou EA, Vyssoulis GP, Psichogios A, Malakou C, Kyrozi EA, Cokkinos DV, Toutouzas PK. Regression of left ventricular hypertrophy results in improvement of QT dispersion in patients with hypertension. Am Heart J 1998, 136:765-768. 10.1016/S0002-8703(98)70119-X, 9812069.
39. Fogari R, Zoppi A, Maffioli P, Monti C, Lazzari P, Mugellini A, Derosa G. Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2012, 14:341-347. 10.1111/j.1463-1326.2011.01535.x, 22074122.
40. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358:580-591. 10.1056/NEJMoa0706245, 18256393.
41. Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. 10.1016/S0140-6736(08)60761-8, 18191683.
42. Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol 2013, 12:135. 10.1186/1475-2840-12-135, 24053606.
43. Chow E, Bernjak A, Williams S, Fawdry RA, Hibbert S, Freeman J, Sheridan PJ, Heller SR. Risk of cardiac arrhythmias during hypoglycemia in patients with type 2 diabetes and cardiovascular risk. Diabetes 2014, 63:1738-1747. 10.2337/db13-0468, 24757202.
44. Beom JW, Kim JM, Chung EJ, Kim JY, Ko SY, Na SD, Kim CH, Park G, Kang MY. Corrected QT interval prolongation during severe hypoglycemia without hypokalemia in patients with type 2 diabetes. Diabetes Metab J 2013, 37:190-195. 10.4093/dmj.2013.37.3.190, 23807922.
45. Ling S, Nguyen HT. Ventricular repolarization variability for hypoglycemia detection. Conf Proc IEEE Eng Med Biol Soc 2011, 2011:7961-7964. 22256187.